Background of the antisense oligonucleotide approach to chemotherapy.
Zamecnik
P
P
Hybridon, Inc., Cambridge, MA 02139, USA.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology; D000998:Antiviral Agents / Q000737:chemistry / Q000266:history / Q000494:pharmacology; D001358:Avian Sarcoma Viruses / Q000187:drug effects / Q000235:genetics; D001424:Bacterial Infections / Q000188:drug therapy; D002642:Chick Embryo; D004337:Drug Carriers; D004352:Drug Resistance, Microbial; D004358:Drug Therapy / Q000266:history*; D049673:History, 20th Century; D006801:Humans; D008404:Massachusetts; D008967:Molecular Biology / Q000266:history; D009161:Mycobacterium / Q000187:drug effects / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000266:history* / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D004337:Drug Carriers; D016376:Oligonucleotides, Antisense